461 related articles for article (PubMed ID: 19239382)
21. Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.
Yuasa K; Sakamoto M; Miyagoe-Suzuki Y; Tanouchi A; Yamamoto H; Li J; Chamberlain JS; Xiao X; Takeda S
Gene Ther; 2002 Dec; 9(23):1576-88. PubMed ID: 12424610
[TBL] [Abstract][Full Text] [Related]
22. Antisense-induced exon skipping for duplications in Duchenne muscular dystrophy.
Aartsma-Rus A; Janson AA; van Ommen GJ; van Deutekom JC
BMC Med Genet; 2007 Jul; 8():43. PubMed ID: 17612397
[TBL] [Abstract][Full Text] [Related]
23. [Current status and perspective of gene therapy on dystrophic animal model].
Takeda S
Rinsho Shinkeigaku; 2004 Nov; 44(11):911-3. PubMed ID: 15651329
[TBL] [Abstract][Full Text] [Related]
24. A canine minidystrophin is functional and therapeutic in mdx mice.
Wang B; Li J; Qiao C; Chen C; Hu P; Zhu X; Zhou L; Bogan J; Kornegay J; Xiao X
Gene Ther; 2008 Aug; 15(15):1099-106. PubMed ID: 18432277
[TBL] [Abstract][Full Text] [Related]
25. Systemic delivery of morpholino oligonucleotide restores dystrophin expression bodywide and improves dystrophic pathology.
Alter J; Lou F; Rabinowitz A; Yin H; Rosenfeld J; Wilton SD; Partridge TA; Lu QL
Nat Med; 2006 Feb; 12(2):175-7. PubMed ID: 16444267
[TBL] [Abstract][Full Text] [Related]
26. In vivo comparison of 2'-O-methyl phosphorothioate and morpholino antisense oligonucleotides for Duchenne muscular dystrophy exon skipping.
Heemskerk HA; de Winter CL; de Kimpe SJ; van Kuik-Romeijn P; Heuvelmans N; Platenburg GJ; van Ommen GJ; van Deutekom JC; Aartsma-Rus A
J Gene Med; 2009 Mar; 11(3):257-66. PubMed ID: 19140108
[TBL] [Abstract][Full Text] [Related]
27. Forced myofiber regeneration promotes dystrophin gene transfer and improved muscle function despite advanced disease in old dystrophic mice.
Guibinga GH; Ebihara S; Nalbantoglu J; Holland P; Karpati G; Petrof BJ
Mol Ther; 2001 Nov; 4(5):499-507. PubMed ID: 11708887
[TBL] [Abstract][Full Text] [Related]
28. Effective rescue of dystrophin improves cardiac function in dystrophin-deficient mice by a modified morpholino oligomer.
Wu B; Moulton HM; Iversen PL; Jiang J; Li J; Li J; Spurney CF; Sali A; Guerron AD; Nagaraju K; Doran T; Lu P; Xiao X; Lu QL
Proc Natl Acad Sci U S A; 2008 Sep; 105(39):14814-9. PubMed ID: 18806224
[TBL] [Abstract][Full Text] [Related]
29. Therapeutic strategies for Duchenne and Becker dystrophies.
Voisin V; de la Porte S
Int Rev Cytol; 2004; 240():1-30. PubMed ID: 15548414
[TBL] [Abstract][Full Text] [Related]
30. Theoretic applicability of antisense-mediated exon skipping for Duchenne muscular dystrophy mutations.
Aartsma-Rus A; Fokkema I; Verschuuren J; Ginjaar I; van Deutekom J; van Ommen GJ; den Dunnen JT
Hum Mutat; 2009 Mar; 30(3):293-9. PubMed ID: 19156838
[TBL] [Abstract][Full Text] [Related]
31. Restoration of all dystrophin protein interactions by functional domains in trans does not rescue dystrophy.
Gardner KL; Kearney JA; Edwards JD; Rafael-Fortney JA
Gene Ther; 2006 May; 13(9):744-51. PubMed ID: 16307000
[TBL] [Abstract][Full Text] [Related]
32. DMD pseudoexon mutations: splicing efficiency, phenotype, and potential therapy.
Gurvich OL; Tuohy TM; Howard MT; Finkel RS; Medne L; Anderson CB; Weiss RB; Wilton SD; Flanigan KM
Ann Neurol; 2008 Jan; 63(1):81-9. PubMed ID: 18059005
[TBL] [Abstract][Full Text] [Related]
33. Gene therapy for muscle disease.
Miyagoe-Suzuki Y; Takeda S
Exp Cell Res; 2010 Nov; 316(18):3087-92. PubMed ID: 20580709
[TBL] [Abstract][Full Text] [Related]
34. Stable transduction of myogenic cells with lentiviral vectors expressing a minidystrophin.
Li S; Kimura E; Fall BM; Reyes M; Angello JC; Welikson R; Hauschka SD; Chamberlain JS
Gene Ther; 2005 Jul; 12(14):1099-108. PubMed ID: 15759015
[TBL] [Abstract][Full Text] [Related]
35. Dystrophin expression in the mdx mouse after localised and systemic administration of a morpholino antisense oligonucleotide.
Fletcher S; Honeyman K; Fall AM; Harding PL; Johnsen RD; Wilton SD
J Gene Med; 2006 Feb; 8(2):207-16. PubMed ID: 16285002
[TBL] [Abstract][Full Text] [Related]
36. Immune responses to dystropin: implications for gene therapy of Duchenne muscular dystrophy.
Ferrer A; Wells KE; Wells DJ
Gene Ther; 2000 Sep; 7(17):1439-46. PubMed ID: 11001363
[TBL] [Abstract][Full Text] [Related]
37. Peptide-morpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy.
Moulton HM; Wu B; Jearawiriyapaisarn N; Sazani P; Lu QL; Kole R
Ann N Y Acad Sci; 2009 Sep; 1175():55-60. PubMed ID: 19796077
[TBL] [Abstract][Full Text] [Related]
38. Systemic human minidystrophin gene transfer improves functions and life span of dystrophin and dystrophin/utrophin-deficient mice.
Wang B; Li J; Fu FH; Xiao X
J Orthop Res; 2009 Apr; 27(4):421-6. PubMed ID: 18973234
[TBL] [Abstract][Full Text] [Related]
39. The value of mammalian models for duchenne muscular dystrophy in developing therapeutic strategies.
Banks GB; Chamberlain JS
Curr Top Dev Biol; 2008; 84():431-53. PubMed ID: 19186250
[TBL] [Abstract][Full Text] [Related]
40. Delivery of AAV2/9-microdystrophin genes incorporating helix 1 of the coiled-coil motif in the C-terminal domain of dystrophin improves muscle pathology and restores the level of α1-syntrophin and α-dystrobrevin in skeletal muscles of mdx mice.
Koo T; Malerba A; Athanasopoulos T; Trollet C; Boldrin L; Ferry A; Popplewell L; Foster H; Foster K; Dickson G
Hum Gene Ther; 2011 Nov; 22(11):1379-88. PubMed ID: 21453126
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
